Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tamer M Fouad

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Breast (Edinburgh, Scotland)|August 10, 2015
Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015Dimitrios Zardavas, Tamer M Fouad, Martine Piccart
Women'S Health (London, England)|March 2, 2010
Acute leukemia in womenFrancesco Lo-Coco, Tamer M Fouad, Safaa M Ramadan
Advances in Experimental Medicine and Biology|May 14, 2014
The role of inflammation in inflammatory breast cancerTamer M Fouad, Takahiro Kogawa, James M Reuben, et al.
Haematologica|December 20, 2011
Acute myeloid leukemia developing in patients with autoimmune diseasesSafaa M Ramadan, Tamer M Fouad, Valentina Summa, et al.
Global Public Health|September 19, 2017
The 'indirect costs' of underfunding foreign partners in global health research: A case studyJohanna T Crane, Irene Andia Biraro, Tamer M Fouad, et al.
Clinical Lung Cancer|November 25, 2021
Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN TrialJohn V Heymach, Tetsuya Mitsudomi, David Harpole, et al.
The Surgical Clinics of North America|July 15, 2018
Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast CancerArjun Menta, Tamer M Fouad, Anthony Lucci, et al.
Journal of Cancer|July 2, 2019
The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancerJing Ning, Tamer M Fouad, Heather Lin, et al.
Therapeutic Advances in Medical Oncology|August 8, 2018
Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozoleHiroshi Umehara, Yoshimi Maekawa, Fumito Koizumi, et al.
Clinical Breast Cancer|September 27, 2014
Clinical characteristics and outcome of bone-only metastasis in inflammatory and noninflammatory breast cancersMegumi Kai, Takahiro Kogawa, Diane D Liu, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Breast (Edinburgh, Scotland)|August 10, 2015
Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015Dimitrios Zardavas, Tamer M Fouad, Martine Piccart
Women'S Health (London, England)|March 2, 2010
Acute leukemia in womenFrancesco Lo-Coco, Tamer M Fouad, Safaa M Ramadan
Advances in Experimental Medicine and Biology|May 14, 2014
The role of inflammation in inflammatory breast cancerTamer M Fouad, Takahiro Kogawa, James M Reuben, et al.
Haematologica|December 20, 2011
Acute myeloid leukemia developing in patients with autoimmune diseasesSafaa M Ramadan, Tamer M Fouad, Valentina Summa, et al.
Global Public Health|September 19, 2017
The 'indirect costs' of underfunding foreign partners in global health research: A case studyJohanna T Crane, Irene Andia Biraro, Tamer M Fouad, et al.
Clinical Lung Cancer|November 25, 2021
Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN TrialJohn V Heymach, Tetsuya Mitsudomi, David Harpole, et al.
The Surgical Clinics of North America|July 15, 2018
Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast CancerArjun Menta, Tamer M Fouad, Anthony Lucci, et al.
Journal of Cancer|July 2, 2019
The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancerJing Ning, Tamer M Fouad, Heather Lin, et al.
Therapeutic Advances in Medical Oncology|August 8, 2018
Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozoleHiroshi Umehara, Yoshimi Maekawa, Fumito Koizumi, et al.
Clinical Breast Cancer|September 27, 2014
Clinical characteristics and outcome of bone-only metastasis in inflammatory and noninflammatory breast cancersMegumi Kai, Takahiro Kogawa, Diane D Liu, et al.
Pageof 3